Cargando…

Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib‐resistance of EML4‐ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors

Crizotinib, a first‐generation anaplastic lymphoma kinase (ALK) tyrosine‐kinase inhibitor, is known to be effective against echinoderm microtubule‐associated protein‐like 4 (EML4)‐ALK‐positive non‐small cell lung cancers. Nonetheless, the tumors subsequently become resistant to crizotinib and recur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taniguchi, Hirokazu, Takeuchi, Shinji, Fukuda, Koji, Nakagawa, Takayuki, Arai, Sachiko, Nanjo, Shigeki, Yamada, Tadaaki, Yamaguchi, Hiroyuki, Mukae, Hiroshi, Yano, Seiji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5276841/ https://www.ncbi.nlm.nih.gov/pubmed/27783866 http://dx.doi.org/10.1111/cas.13111

Ejemplares similares

Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells
por: Tanimoto, Azusa, et al.
Publicado: (2014)

Compatibility of intravitreally applied epidermal growth factor and amphiregulin
por: Bikbov, Mukharram M., et al.
Publicado: (2021)

Fibroblast growth factor receptor 4 increases epidermal growth factor receptor (EGFR) signaling by inducing amphiregulin expression and attenuates response to EGFR inhibitors in colon cancer
por: Hong, Chang‐Soo, et al.
Publicado: (2020)

Targeting the epidermal growth factor receptor
por: El-Rayes, B F, et al.
Publicado: (2004)

Epidermal growth factor receptor in glioblastoma
por: Xu, Hongsheng, et al.
Publicado: (2017)

Expression of Amphiregulin, a Novel Gene of the Epidermal Growth Factor Family, in Human Gastric Carcinomas
por: Kitadai, Yasuhiko, et al.
Publicado: (1993)

Serum Amphiregulin and Heparin-Binding Epidermal Growth Factor as Biomarkers in Patients with Idiopathic Inflammatory Myopathy
por: Hanata, Norio, et al.
Publicado: (2021)

Transforming growth factor alpha and epidermal growth factor levels in bladder cancer and their relationship to epidermal growth factor receptor.
por: Mellon, J. K., et al.
Publicado: (1996)

Expression and localization of epidermal growth factor, transforming growth factor-α and epidermal growth factor receptor in the canine testis
por: TAMADA, Hiromichi, et al.
Publicado: (2015)

Epidermal Growth Factor Receptor in Pancreatic Cancer
por: Oliveira-Cunha, Melissa, et al.
Publicado: (2011)

Epidermal Growth Factor Receptors and Breast Cancer
por: Farndon, J. R., et al.
Publicado: (1989)

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
por: Chang, Shih-Chieh, et al.
Publicado: (2011)

Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancer
por: Sobani, Zain A, et al.
Publicado: (2016)

Expression of transforming growth factor alpha, epidermal growth factor receptor and epidermal growth factor in precursor lesions to gastric carcinoma.
por: Filipe, M. I., et al.
Publicado: (1995)

Response to a Combination of Full-Dose Osimertinib and Ceritinib in a Non-Small Cell Lung Cancer Patient with EML4-ALK Rearrangement and Epidermal Growth Factor Receptor Co-Mutation
por: Nguyen, Thai Hoa Thi, et al.
Publicado: (2021)

Intravesicular epidermal growth factor receptor subject to retrograde trafficking drives epidermal growth factor-dependent migration
por: Maisel, Sabrina, et al.
Publicado: (2017)

Crizotinib-Resistant Mutants of EML4-ALK Identified Through an Accelerated Mutagenesis Screen
por: Zhang, Sen, et al.
Publicado: (2011)

An observational study of the epidermal growth factor receptor-tyrosine kinase inhibitor resistance mechanism in epidermal growth factor receptor gene mutation-positive non-small cell lung cancer
por: Yoshimura, Akihiro, et al.
Publicado: (2018)

Proinflammatory role of amphiregulin, an epidermal growth factor family member whose expression is augmented in rheumatoid arthritis patients
por: Yamane, Shoji, et al.
Publicado: (2008)

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
por: Tao, Hong, et al.
Publicado: (2022)

Epidermal growth factor receptor tyrosine kinase inhibitors
por: Ranson, M
Publicado: (2004)

Evaluation of epidermal growth factor receptors in bladder tumours.
por: Berger, M. S., et al.
Publicado: (1987)

Allosteric regulation of the epidermal growth factor receptor kinase
Publicado: (1986)

The epidermal growth factor receptor family in breast cancer
por: Koutras, Angelos K, et al.
Publicado: (2008)

Inhibiting Epidermal Growth Factor Receptor at a Distance
por: Sinclair, Julie K.-L., et al.
Publicado: (2014)

The epidermal growth factor receptor (EGRF) in lung cancer
por: Carcereny, Enric, et al.
Publicado: (2015)

Assessment of epidermal growth factor receptor status in glioblastomas
por: Zhu, Hui-Jun, et al.
Publicado: (2013)

Epidermal growth factor receptor function in the human urothelium
por: Wasén, C., et al.
Publicado: (2018)

Targeting the Cardiotoxicity of Epidermal Growth Factor Receptor Inhibitors
por: Uprety, Dipesh, et al.
Publicado: (2020)

Epidermal Growth Factor Receptor Expression in the Corneal Epithelium
por: Peterson, Joanne L., et al.
Publicado: (2021)

Modulation of Pathological Pain by Epidermal Growth Factor Receptor
por: Borges, Jazlyn P., et al.
Publicado: (2021)

Interactions between the receptors for platelet-derived growth factor and epidermal growth factor
Publicado: (1983)

Employment of the Epidermal Growth Factor Receptor in Growth Factor–Independent Signaling Pathways
por: Carpenter, Graham
Publicado: (1999)

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?
por: Banno, Eri, et al.
Publicado: (2016)

Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives
por: Saito, Ayumi, et al.
Publicado: (2021)

Crizotinib: aseptic abscesses in multiple organs during treatment of EML4-ALK-positive NSCLC
por: Weber, Daniel, et al.
Publicado: (2021)

Ip-10 Inhibits Epidermal Growth Factor–Induced Motility by Decreasing Epidermal Growth Factor Receptor–Mediated Calpain Activity
por: Shiraha, Hidenori, et al.
Publicado: (1999)

Association Study of Polymorphisms of Epidermal Growth Factor and Epidermal Growth Factor Receptor With Benign Prostatic Hyperplasia in a Korean Population
por: Kim, Su Kang, et al.
Publicado: (2016)

Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2
por: Tanaka, Hidekazu, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_jpou1g64ahqb22mpmvmdrbt32p